

CORRECTION

Open Access



Correction to: Trimodally treatment for stage IIIa NSCLC patients increases survival while not effecting surgical mortality or complexity

Dan Aravot^{1,4†}, Yaron D. Barac^{1,4*†}, Efrat Krutzwald-Josefson¹, Aaron M. Allen², Dov Flex², Nir Peled², Mordechai R. Kramer^{3,4}, Yuri Peysakhovich¹ and Milton Saute^{1,4}

Correction to: J Cardiothorac Surg (2019) 14:7

<https://doi.org/10.1186/s13019-018-0829-z>

The original article [1] contained an error whereby all authors' names were mistakenly inverted. This error has now been corrected.

Author details

¹Department of Cardiothoracic Surgery, Rabin Medical Center, Beilinson Campus, Petach-Tikva, Israel. ²Department of Oncology, Rabin Medical Center, Beilinson Campus, Petach-Tikva, Israel. ³Department of Pulmonary Medicine, Rabin Medical Center, Beilinson Campus, Petach-Tikva, Israel. ⁴Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Received: 5 February 2019 Accepted: 5 February 2019

Published online: 12 February 2019

Reference

1. Aravot D, et al. Trimodally treatment for stage IIIa NSCLC patients increases survival while not effecting surgical mortality or complexity. *J Cardiothorac Surg.* 2019;14:7 <https://doi.org/10.1186/s13019-018-0829-z>.

* Correspondence: aronbar@icloud.com

†Dan Aravot and Yaron D. Barac contributed equally to this work.

¹Department of Cardiothoracic Surgery, Rabin Medical Center, Beilinson Campus, Petach-Tikva, Israel

⁴Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel

Full list of author information is available at the end of the article

